-
Something wrong with this record ?
A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer
S. Novotna, K. Valentova, J. Fricova, E. Richterova, S. Harabisova, F. Bullier, F. Trinquet, . ,
Language English Country United States
Document type Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2002-01-01 to 2 months ago
Medline Complete (EBSCOhost)
from 2012-09-01 to 2015-07-31
Nursing & Allied Health Database (ProQuest)
from 2002-01-01 to 2 months ago
Health & Medicine (ProQuest)
from 2002-01-01 to 2 months ago
Health Management Database (ProQuest)
from 2002-01-01 to 2 months ago
- MeSH
- Administration, Sublingual MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Fentanyl administration & dosage adverse effects therapeutic use MeSH
- Cross-Over Studies MeSH
- Middle Aged MeSH
- Humans MeSH
- Pain Management MeSH
- Disease Management MeSH
- Pain Measurement MeSH
- Neoplasms drug therapy MeSH
- Analgesics, Opioid administration & dosage adverse effects therapeutic use MeSH
- Breakthrough Pain drug therapy MeSH
- Aged MeSH
- Tablets MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: Oromucosal fentanyl is currently used for the treatment of breakthrough pain (BTP) in opioid-treated cancer patients. Ethypharm developed a sublingual formulation of fentanyl suprabioavailable to oral transmucosal fentanyl citrate with a higher early systemic exposure and a shorter Tmax. OBJECTIVES: This study evaluated the efficacy and safety profile of fentanyl Ethypharm (FE) in relieving BTP in opioid-treated cancer patients. METHODS: Opioid-treated adult cancer patients, experiencing 1 to 4 episodes of BTP per day, were included in the study. After an open-label titration period to identify an optimal dose that would provide adequate pain relief for 2 consecutive episodes of BTP with an acceptable level of adverse events, patients were randomly assigned to a double-blind, placebo-controlled, crossover period with 1 of 13 prespecified sequences of 9 tablets (6 tablets of FE of the dose identified during the open-label titration and 3 placebo). Pain intensity and pain relief were recorded at 3, 6, 10, 15, 30, and 60 minutes after study drug administration. Adverse events were recorded. The primary end point was the sum of pain intensity differences (SPID) at 30 minutes. RESULTS: The distribution of optimal dosages of FE was as follows: 133 μg, 35.9%; 267 μg, 30.8%; 400 μg, 14.1%; 533 μg, 12.8%; and 800 μg, 6.4%. In the modified intention-to-treat population (n = 73), FE significantly improved mean (SE) SPID compared with placebo at 30 minutes (75.0 [49.8] vs 52.5 [52.8]; P < 0.0001). FE significantly improved SPID, pain intensity difference, and pain relief compared with placebo from 6 to 60 minutes' postadministration. Patients with BTP who received placebo required the use of rescue medication more often than those treated with FE (38.4% vs 17.5%; P < 0.0001). A significant improvement in pain scores (>33% and >50% reductions) was also reported for BTP treated with FE. Pain scores for patients with BTP with a neuropathic component (13 patients) were lower with FE than for those receiving placebo, but the difference was not significant. AEs were of mild or moderate severity and typical of opioid drugs. CONCLUSIONS: This newly developed galenic formulation with a higher early systemic exposure and a shorter Tmax compared with oral transmucosal fentanyl citrate makes FE a particularly suitable formulation for the management of BTP in opioid-treated cancer patients due to the very rapid onset of action. FE provided significant improvement in pain intensity of BTP compared with placebo as early as 6 minutes' postadministration with a sustained effect over 60 minutes. FE was well tolerated by patients. ClinicalTrials.gov identifier: NCT 01842893.
Ambulance lecby chronicke bolesti a paliativni mediciny Hradec Kralove
ICTA PM Fontaine les Dijon France
Metstska nemocnice Ostrava Ostrava Czech Republic
Nemocnice s poliklinikou v Semilech Semily
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010792
- 003
- CZ-PrNML
- 005
- 20241024103440.0
- 007
- ta
- 008
- 160408s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clinthera.2014.01.006 $2 doi
- 024 7_
- $a 10.1016/j.clinthera.2014.01.006 $2 doi
- 035 __
- $a (PubMed)24508417
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Novotna, Stanislava $u Vysokomytska nemocnice, Vysoke Myto.
- 245 12
- $a A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer / $c S. Novotna, K. Valentova, J. Fricova, E. Richterova, S. Harabisova, F. Bullier, F. Trinquet, . ,
- 520 9_
- $a BACKGROUND: Oromucosal fentanyl is currently used for the treatment of breakthrough pain (BTP) in opioid-treated cancer patients. Ethypharm developed a sublingual formulation of fentanyl suprabioavailable to oral transmucosal fentanyl citrate with a higher early systemic exposure and a shorter Tmax. OBJECTIVES: This study evaluated the efficacy and safety profile of fentanyl Ethypharm (FE) in relieving BTP in opioid-treated cancer patients. METHODS: Opioid-treated adult cancer patients, experiencing 1 to 4 episodes of BTP per day, were included in the study. After an open-label titration period to identify an optimal dose that would provide adequate pain relief for 2 consecutive episodes of BTP with an acceptable level of adverse events, patients were randomly assigned to a double-blind, placebo-controlled, crossover period with 1 of 13 prespecified sequences of 9 tablets (6 tablets of FE of the dose identified during the open-label titration and 3 placebo). Pain intensity and pain relief were recorded at 3, 6, 10, 15, 30, and 60 minutes after study drug administration. Adverse events were recorded. The primary end point was the sum of pain intensity differences (SPID) at 30 minutes. RESULTS: The distribution of optimal dosages of FE was as follows: 133 μg, 35.9%; 267 μg, 30.8%; 400 μg, 14.1%; 533 μg, 12.8%; and 800 μg, 6.4%. In the modified intention-to-treat population (n = 73), FE significantly improved mean (SE) SPID compared with placebo at 30 minutes (75.0 [49.8] vs 52.5 [52.8]; P < 0.0001). FE significantly improved SPID, pain intensity difference, and pain relief compared with placebo from 6 to 60 minutes' postadministration. Patients with BTP who received placebo required the use of rescue medication more often than those treated with FE (38.4% vs 17.5%; P < 0.0001). A significant improvement in pain scores (>33% and >50% reductions) was also reported for BTP treated with FE. Pain scores for patients with BTP with a neuropathic component (13 patients) were lower with FE than for those receiving placebo, but the difference was not significant. AEs were of mild or moderate severity and typical of opioid drugs. CONCLUSIONS: This newly developed galenic formulation with a higher early systemic exposure and a shorter Tmax compared with oral transmucosal fentanyl citrate makes FE a particularly suitable formulation for the management of BTP in opioid-treated cancer patients due to the very rapid onset of action. FE provided significant improvement in pain intensity of BTP compared with placebo as early as 6 minutes' postadministration with a sustained effect over 60 minutes. FE was well tolerated by patients. ClinicalTrials.gov identifier: NCT 01842893.
- 650 _2
- $a aplikace sublinguální $7 D000286
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a opioidní analgetika $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000701
- 650 _2
- $a průlomová bolest $x farmakoterapie $7 D059390
- 650 _2
- $a klinické křížové studie $7 D018592
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fentanyl $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D005283
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádory $x farmakoterapie $7 D009369
- 650 _2
- $a management bolesti $7 D059408
- 650 _2
- $a měření bolesti $7 D010147
- 650 _2
- $a tablety $7 D013607
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Valentova, Klara $u Nemocnice s poliklinikou v Semilech, Semily.
- 700 1_
- $a Fricová, Jitka, $d 1971- $u Vseobecna fakultni nemocnice, Prague. $7 xx0105524
- 700 1_
- $a Richterova, Eva $u Ambulance lecby chronicke bolesti a paliativni mediciny, Hradec Kralove.
- 700 1_
- $a Harabisova, Sarka $u Metstska nemocnice Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Bullier, Françoise $u ICTA PM, Fontaine les Dijon, France. Electronic address: trinquet.francoise@ethypharm.com.
- 700 1_
- $a Trinquet, Françoise $u Ethypharm, Saint Cloud, France.
- 700 1_
- $a ,
- 773 0_
- $w MED00001165 $t Clinical therapeutics $x 1879-114X $g Roč. 36, č. 3 (2014), s. 357-67
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24508417 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20241024103434 $b ABA008
- 999 __
- $a ok $b bmc $g 1114221 $s 935160
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 36 $c 3 $d 357-67 $e 20140205 $i 1879-114X $m Clinical therapeutics $n Clin Ther $x MED00001165
- LZP __
- $a Pubmed-20160408